View Future GrowthARCpoint 과거 순이익 실적과거 기준 점검 0/6ARCpoint 의 수입은 연평균 -15.8%의 비율로 감소해 온 반면, Healthcare 산업은 연평균 4%의 비율로 증가했습니다. 매출은 연평균 42.2%의 비율로 감소해 왔습니다.핵심 정보-15.79%순이익 성장률-111.47%주당순이익(EPS) 성장률Healthcare 산업 성장률8.50%매출 성장률-42.16%자기자본이익률n/a순이익률-349.32%최근 순이익 업데이트31 Dec 2025최근 과거 실적 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Jun 11ARCpoint Inc. Announces CEO ChangesARCpoint Inc. announced that its Board of Directors had appointed Peter Kendall as Interim Chief Executive Officer of the Company, effective June 9, 2026. Mr. Kendall’s appointment remains subject to acceptance by the TSX Venture Exchange, including acceptance of the Exchange’s required Personal Information Form and completion of customary Exchange review and verification procedures. In connection with Mr. Kendall’s appointment, John Constantine has stepped down as Chief Executive Officer of the Company and will transition to a role focused on supporting the Company’s sales, marketing and commercial development efforts, including the commercial development of the MyARCpointLabs technology platform. Mr. Constantine will continue to serve as a director of the Company. Peter Kendall has more than twenty years of healthcare commercialization experience. His prior roles include President and Chief Commercialization Officer of AI/ML Innovations Inc., Chief Executive Officer of Yurek Pharmacy Group, and National Director at Medisys Health Group, subsequently acquired by TELUS Health. Mr. Kendall’s initial engagement is for a term of 90 days. During this period, Mr. Kendall will work with the Board and management to assess the Company's business model, MAPL technology platform, commercial relationships, assets and strategic direction, and to provide recommendations to the Board on the best commercial and financial path forward for the Company and its stakeholders.공시 • Jun 10Arcpoint Inc. Announces Step Down of John Constantine as PresidentARCpoint Inc. announced that John Constantine has stepped down as President of the Company and will transition to a role focused on supporting the Company’s sales, marketing and commercial development efforts, including the commercial development of the MyARCpointLabs technology platform. Mr. Constantine will continue to serve as a director of the Company. The Company’s Board members remain Zelong “Roger” He, David Keys, John Constantine and Adam Ho.공시 • Apr 30Arcpoint Inc. Announces Felix Mirando Resignation of Board MemberARCpoint Inc. reports that Felix Mirando has resigned as a member of the Company’s Board of Directors for personal reasons, effective April 28, 2026.공시 • Jul 02ARCpoint Inc., Annual General Meeting, Aug 25, 2025ARCpoint Inc., Annual General Meeting, Aug 25, 2025.공시 • Mar 09ARCpoint Inc. announced that it has received CAD 0.8 million in fundingOn March 7, 2025, ARCpoint Inc., closed the transaction. As a part of the transaction, the company paid CAD 36,057.60 as cash commission, issued 428,400 finder’s shares, 536,400 finder’s warrants. The transaction included participation from Felix Mirando and Adam Ho, purchased or acquired direction or control over a total of 764,199 units as part of the offering.공시 • Jan 31ARCpoint Inc. announced that it expects to receive CAD 0.8 million in fundingARCpoint Inc. announced a non-brokered private placement to issue 10,000,000 units at issue price of CAD 0.08 per unit for gross proceeds of CAD 800,000 on January 31, 2025. Each Unit will be comprised of one Class A Subordinate Voting Share of the Company and one warrant to purchase an additional Share at CAD 0.12 for 24 months from closing. The Offering is subject to all necessary regulatory approvals including acceptance from the TSX Venture Exchange. All securities issued in connection with the Offering will be subject to a four-month hold period from the closing date under applicable Canadian securities laws, in addition to such other restrictions as may apply under applicable securities laws of jurisdictions outside Canada. Subject to compliance with applicable securities laws and the approval of the TSX Venture Exchange, finders’ fees may be payable to eligible arm’s length persons with respect to certain subscriptions accepted by the Company.공시 • Dec 31An undisclosed buyer entered into an agreement to acquire 68% stake in Achieve Behavioral Health Greenville, LLC from ARCpoint Inc. (TSXV:ARC) for $0.48 million.An undisclosed buyer entered into an agreement to acquire 68% stake in Achieve Behavioral Health Greenville, LLC from ARCpoint Inc. (TSXV:ARC) for $0.48 million on December 30, 2024. A cash consideration of $0.48 million will be paid by the buyer.공시 • Aug 01ARCpoint Inc. announced that it has received CAD 1.004175 million in fundingOn July 31, 2024, ARCpoint Inc. closed the transaction. The company issued 13,389,000 subordinate voting shares of the Company at a price of CAD 0.075 per share for the gross proceeds of up to CAD 1,004,175. In connection with the closing of the offering the company issued 670,900 finder’s shares, 1,013,900 finder’s warrants and paid a cash commission of CAD 60,834 to certain arm’s length finders. Each finder’s warrant entitles the holder thereof to purchase one share at a price of CAD 0.075 per finder’s warrant share until July 31, 2026. The offering remains subject to final acceptance from the TSX Venture Exchange. All securities issued in connection with the offering are subject to a four-month hold period from the closing date under applicable Canadian securities laws, in addition to such other restrictions as may apply under applicable securities laws of jurisdictions outside Canada.매출 및 비용 세부 내역ARCpoint가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이OTCPK:ARCP.F 매출, 비용 및 순이익 (USD Millions)날짜매출순이익일반관리비연구개발비31 Dec 251-22030 Sep 251-33030 Jun 25334031 Mar 25426031 Dec 24616030 Sep 246-18030 Jun 247-78031 Mar 247-88031 Dec 237-99030 Sep 236-1210030 Jun 236-1210031 Mar 237-1110031 Dec 2211-810030 Sep 2215-19030 Jun 221928031 Mar 221947031 Dec 211967031 Dec 2013640양질의 수익: ARCP.F 은(는) 현재 수익성이 없습니다.이익 마진 증가: ARCP.F는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: ARCP.F은 수익성이 없으며 지난 5년 동안 손실이 연평균 15.8% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 ARCP.F의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: ARCP.F은 수익성이 없어 지난 해 수익 성장률을 Healthcare 업계(15.3%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: ARCP.F의 부채가 자산을 초과하여 자본 수익률을 계산하기 어렵습니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YHealthcare 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/07 00:32종가2026/05/05 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스ARCpoint Inc.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Jun 11ARCpoint Inc. Announces CEO ChangesARCpoint Inc. announced that its Board of Directors had appointed Peter Kendall as Interim Chief Executive Officer of the Company, effective June 9, 2026. Mr. Kendall’s appointment remains subject to acceptance by the TSX Venture Exchange, including acceptance of the Exchange’s required Personal Information Form and completion of customary Exchange review and verification procedures. In connection with Mr. Kendall’s appointment, John Constantine has stepped down as Chief Executive Officer of the Company and will transition to a role focused on supporting the Company’s sales, marketing and commercial development efforts, including the commercial development of the MyARCpointLabs technology platform. Mr. Constantine will continue to serve as a director of the Company. Peter Kendall has more than twenty years of healthcare commercialization experience. His prior roles include President and Chief Commercialization Officer of AI/ML Innovations Inc., Chief Executive Officer of Yurek Pharmacy Group, and National Director at Medisys Health Group, subsequently acquired by TELUS Health. Mr. Kendall’s initial engagement is for a term of 90 days. During this period, Mr. Kendall will work with the Board and management to assess the Company's business model, MAPL technology platform, commercial relationships, assets and strategic direction, and to provide recommendations to the Board on the best commercial and financial path forward for the Company and its stakeholders.
공시 • Jun 10Arcpoint Inc. Announces Step Down of John Constantine as PresidentARCpoint Inc. announced that John Constantine has stepped down as President of the Company and will transition to a role focused on supporting the Company’s sales, marketing and commercial development efforts, including the commercial development of the MyARCpointLabs technology platform. Mr. Constantine will continue to serve as a director of the Company. The Company’s Board members remain Zelong “Roger” He, David Keys, John Constantine and Adam Ho.
공시 • Apr 30Arcpoint Inc. Announces Felix Mirando Resignation of Board MemberARCpoint Inc. reports that Felix Mirando has resigned as a member of the Company’s Board of Directors for personal reasons, effective April 28, 2026.
공시 • Jul 02ARCpoint Inc., Annual General Meeting, Aug 25, 2025ARCpoint Inc., Annual General Meeting, Aug 25, 2025.
공시 • Mar 09ARCpoint Inc. announced that it has received CAD 0.8 million in fundingOn March 7, 2025, ARCpoint Inc., closed the transaction. As a part of the transaction, the company paid CAD 36,057.60 as cash commission, issued 428,400 finder’s shares, 536,400 finder’s warrants. The transaction included participation from Felix Mirando and Adam Ho, purchased or acquired direction or control over a total of 764,199 units as part of the offering.
공시 • Jan 31ARCpoint Inc. announced that it expects to receive CAD 0.8 million in fundingARCpoint Inc. announced a non-brokered private placement to issue 10,000,000 units at issue price of CAD 0.08 per unit for gross proceeds of CAD 800,000 on January 31, 2025. Each Unit will be comprised of one Class A Subordinate Voting Share of the Company and one warrant to purchase an additional Share at CAD 0.12 for 24 months from closing. The Offering is subject to all necessary regulatory approvals including acceptance from the TSX Venture Exchange. All securities issued in connection with the Offering will be subject to a four-month hold period from the closing date under applicable Canadian securities laws, in addition to such other restrictions as may apply under applicable securities laws of jurisdictions outside Canada. Subject to compliance with applicable securities laws and the approval of the TSX Venture Exchange, finders’ fees may be payable to eligible arm’s length persons with respect to certain subscriptions accepted by the Company.
공시 • Dec 31An undisclosed buyer entered into an agreement to acquire 68% stake in Achieve Behavioral Health Greenville, LLC from ARCpoint Inc. (TSXV:ARC) for $0.48 million.An undisclosed buyer entered into an agreement to acquire 68% stake in Achieve Behavioral Health Greenville, LLC from ARCpoint Inc. (TSXV:ARC) for $0.48 million on December 30, 2024. A cash consideration of $0.48 million will be paid by the buyer.
공시 • Aug 01ARCpoint Inc. announced that it has received CAD 1.004175 million in fundingOn July 31, 2024, ARCpoint Inc. closed the transaction. The company issued 13,389,000 subordinate voting shares of the Company at a price of CAD 0.075 per share for the gross proceeds of up to CAD 1,004,175. In connection with the closing of the offering the company issued 670,900 finder’s shares, 1,013,900 finder’s warrants and paid a cash commission of CAD 60,834 to certain arm’s length finders. Each finder’s warrant entitles the holder thereof to purchase one share at a price of CAD 0.075 per finder’s warrant share until July 31, 2026. The offering remains subject to final acceptance from the TSX Venture Exchange. All securities issued in connection with the offering are subject to a four-month hold period from the closing date under applicable Canadian securities laws, in addition to such other restrictions as may apply under applicable securities laws of jurisdictions outside Canada.